uniQure NV QURE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if QURE is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $5.41
- Day Range
- $5.16–5.40
- 52-Week Range
- $4.76–22.48
- Bid/Ask
- $4.95 / $5.21
- Market Cap
- $248.76 Mil
- Volume/Avg
- 767,714 / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 15.65
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 480
- Website
- https://www.uniqure.com
Comparables
Valuation
Metric
|
QURE
|
NAMS
|
PHVS
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.20 | 6.76 | 5.84 |
Price/Sales | 15.65 | 137.91 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
QURE
NAMS
PHVS
Financial Strength
Metric
|
QURE
|
NAMS
|
PHVS
|
---|---|---|---|
Quick Ratio | 8.44 | 6.86 | 9.85 |
Current Ratio | 8.85 | 6.95 | 10.46 |
Interest Coverage | −6.85 | — | — |
Quick Ratio
QURE
NAMS
PHVS
Profitability
Metric
|
QURE
|
NAMS
|
PHVS
|
---|---|---|---|
Return on Assets (Normalized) | −35.54% | −34.73% | −50.56% |
Return on Equity (Normalized) | −82.34% | −39.45% | −56.14% |
Return on Invested Capital (Normalized) | −55.12% | −41.57% | −56.14% |
Return on Assets
QURE
NAMS
PHVS
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zqyfzmydv | Rkxd | $570.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xfkfxgqv | Rfbzdg | $108.0 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mqcndsh | Ywqjz | $105.6 Bil | |
MRNA
| Moderna Inc | Wrpcgkhw | Zbcxr | $40.8 Bil | |
ARGX
| argenx SE ADR | Cfgcswvqs | Kqzxh | $23.5 Bil | |
BNTX
| BioNTech SE ADR | Hkhtwfgnd | Cfvbh | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Glyjcmhk | Ysslqh | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pcfvqyf | Brwdw | $16.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kllvxtkjfv | Mzsqk | $13.6 Bil | |
INCY
| Incyte Corp | Nryrnghd | Fzhrpv | $12.8 Bil |